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Using the Adeno-associated virus (AAV) as a gene
delivery vehicle, we have constructed a recombinant
vector containing the full length rat preproinsulin
gene (vLP-1). Utilizing the well described non-obese
diabetic (NOD) mouse model, an experimental
group (n 10) of animals were intramuscularly (IM)
injected with 107 rAAV virions containing the
insulin gene and compared to a mock-injected con-
trol group (n 10). Blood glucose (glc) was then
measured weekly for 16 weeks. Data showed that
the experimental group contained 70% euglycemic
animals (defined as glc <200mg/dL) versus 10% of
the control animals (P<.05) at 14 weeks. Mean
weight in the treated group was greater than the
untreated group. Insulin mRNA was detected at the
injection site of all of the treated animals, but not
controls. Complete destruction of islets was con-
firmed by histology ruling out the possibility of
spontaneous reversal of insulinitis. We conclude
that IM delivery of the insulin gene in the NOD
mouse was able to prevent clinical DM up to 14
weeks in a majority of treated animals. Our experi-
mental data suggests that gene therapy may be an
alternative treatment for IDDM in the future.
Keywords: Gene therapy; Diabetes; NOD mouse; Recombi-
nant adeno-associated virus
Abbreviations: Ad2: adenovirus 2; DM: Diabetes mellitus;
rAAV: recombinant adeno-associated virus; Glc: Glucose;
IDDM: Insulin dependent diabetes mellitus; IM: Intra-
muscular; moi: multiplicity of infection; NOD: Non-obese
diabetic; pAAV\AD: helper plasmid; RSV-LTR: Rous sarco-
ma virus long terminal repeat; rI2: rat preproinsulin II gene
INTRODUCTION
Diabetes Mellitus (DM) in humans is the result
of either lack of insulin (Type I) or insulin resis-
tance (Type II). The impact of DM on morbidity
and mortality is considerable. Since the discov-
ery of insulin, DM is considered a manageable
disease, however, secondary complications of
DM are considerable and lead to significant
morbidity and mortality. Alternative strategies
for insulin delivery and the long-term treatment
for type I DM are being actively investigated.
Implantable insulin pumps have been tried, but
technical complications and cost are prohibitive.
Clinical trials using insulin as a prophylactic
agent to delay the onset of DM in patients with
genetic susceptibility are underway. [1] Pancreatic
islet cell transplants have had mixed results; I21
although the results of whole organ pancreas
transplants have improved in the last few years,
the severe shortage of cadaver organs will be a
limiting factor along with additional problems
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associated with life-long immunosuppression.
The prospects of xenotransplantation of islets
appears to have serious immunological, ethical
and infectious problems.
We report here a novel mechanism for insulin
delivery in vivo. It was generally assumed that
gene therapy would be the dominant treatment
for genetic diseases by the mid- to late-90’s.
However, considerable drawbacks involving
immunogenicity of the delivery systems and the
multifactorial nature of most diseases proved a
difficult hurdle to overcome. Since the middle
90’s, new vector delivery systems have emerged
that have allowed more efficient gene delivery
with improved results in the short-term. In par-
ticular, the recombinant adeno-associated virus
(rAAV) appears to be a significant advance
in non-immunogenic gene delivery system. In
addition to an absence of local immune re-
sponse, the rAAV is unique because it estab-
lishes a latent, stable infection with integration
in a site-specific manner. Recent applications
have involved HIV, Cystic Fibrosis, Fanconi
Anemia, Interleukin-2, GMCSF production and
alteration of drug resistance. I31 Furthermore, IM
gene transfer has become the route of choice
due to accessibility, vascularity, and large tissue
mass.[41
MATERIALS AND METHODS
Construction of the Recombinant rAAV
The steps in the construction of recombinant
rAAV containing the rat preproinsulin II gene
(rI2) gene have been described previously. I51
Briefly, the pLP-1 plasmid incorporating the
gene was engineered by releasing the rI2 gene
with a RSV-LTR promoter from pBC I2BI
(ATCC), purified, and inserted into the BamH1
site of rAAV vector plasmid pWP-19. The re-
combinant plasmid (pLP-1), together with
pAAV\AD helper plasmid, was co-transfected
into human kidney carcinoma cell line 293
(ATCC). The rAAV genome was rescued using
helper adenovirus and packaged into mature
AAV virions designated vLP-1. The recombinant
AAV vector stocks were subsequently purified
on cesium chloride equilibrium density gra-
dients followed by DNase I digestion and heat
inactivation at 56C to render free of any origi-
nal plasmid DNA and adenovirus.
Animals
For studies reported herein, we used 11 week
old NOD mice at initiation of the experiments;
60-80% untreated female animals develop
diabetes by approximately 12 weeks. Infectious
virions (1.7 109) were given IM (right thigh) to
10 NOD mice; controls (n 10) were injected
with saline.
End Point
Animals were sacrificed at week 16 and tissues
examined for the presence of rI2 gene as de-
scribed below. Tissues were also examined for
pathological changes by histology.
PCR Methods
Animals were sacrificed to determine expression
of rI2 mRNA. Injection site muscle, muscle
from non-injected site (opposite limb), liver, and
were obtained and placed into Trizol-BRL (Life
Technologies, Inc.). Total RNA (---lug) ex-
tracted from the individual tissues was subject-
ed to RT-PCR using SuperscriptTM RT (Gibco,
BRL). Primers used for rI2 amplification
were 5’-GCTACAGTCGGAAACCATC-3’ and
5’-ACAGGGTAGTGGTGGGCCT-3’, and oligo-
dT (Oligo’s Etc., Wilsonville, Oregon). For
beta-actin amplification the following primers
were used: 5’-CCTGACCCTGAAGTACCCCA-
3’ AND 5’-CGTCAGGCAGCTCATAGCTC-3’.
Reverse transcription was performed according
manufacturer’s directions (SuperscriptTM RT,
Gibco, BRL). PCR was then carried out using
standard methods. I61 The amplified products
were electrophoresed on 1.5% agarose gels,
transferred to nylon membranes (Boeringer
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Mannheim, Indianapolis) and analyzed by
Southern analysis using [ce 32p]-labeled probe
(rI2 or beta-actin). After hybridization, mem-
branes were washed and exposed to X-omat film
(Eastman Kodak) using standard methods. I61
non-responder experimental animals versus con-
trols. The cross-reactivity if this assay with
proinsulin is estimated to be 70% (Linco does
not have purified rat proinsulin-personal com-
munication, Marcia Niss, Linco, St Louis, MO).
Measurement of Blood glc
Blood glc (analyzed by glucometer, Boehringer
Mannheim, Inc.) was determined on day 1, 3,
and at weekly intervals.
Histology
Pancreata were examined histologically for the
presence of insulitis. Other mice tissues were
examined for evidence of cellular infiltration by
H&E stain.
Insulin RIA
Serum was harvested from animals at 1 week,
and at the end of the study. A standard amount
of serum was analyzed using a rat insulin
RIA kit per manufacturers recommendations
(Linco, St. Louis, MO). Insulin was compared
between responder experimental animals and
RESULTS
In the present study, we investigated the effe4t of
IM injection on rAAV containing the rI2 into 11
week old female NOD mice. Experimental and
control animals were randomly divided into 2
groups of 10 animals each. Animals were then
injected IM with vLP-1 or culture media and blood
glc recorded weekly at 3 PM. Animals in the in-
jected group had statistically significant lower
random blood glc levels than controls (Fig. 1A).
Re-evaluation of the raw data using arbitrary
euglycemia cut-offs of 140mg/dL (Fig. 1B) and
200mg/dL (Fig. 1C) showed that the majority of
experimental animals maintained glc levels
below the cutoff (70% at 14 weeks vs. 10% of the
controls).
In addition to improved glc levels, vLP-1-
injected animals had a higher mean weight
(Fig. 2), and appeared visibly more healthy
than controls (Fig. 3). At 16 weeks, the animals
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FIGURE 1A Individual glucose levels for all animals. All glucose levels were measured at the same time weekly. + denoted
the glucose level in experimental animals while denotes the glucose level in control animals.
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FIGURE 1B Kaplan-Meier curve showing percent of euglycemic animals as defined by an arbitrary glucose cutoff of
140mg/dL.
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(200 mg/dL Blood Glucose Cutoff)
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FIGURE 1C Kaplan-Meier curve showing percent of euglycemic animals as defined by an arbitrary glucose cutoff of
200mg/dL.
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FIGURE 2 Mean weight of experimental (n 10) and control (n 10) animals. Weights were measured at the same time
glucose levels were obtained.
Control
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FIGURE 3 Photograph of a representative experimental
and control animal at 14 weeks.
were sacrificed and various tissues were exam-
ined by hematoxylin and eosin (H&E) staining.
The degree of insulinitis in control and exper-
imental animals was found to be equal
(Fig. 4A). In addition, there was no evidence of
immune infiltrate at the injection site or in
other tissues (Fig. 4B). We stained islets of
rAAV injected animals with anti-insulin anti-
body and found that insulin producing beta
cells were not seen in these islets (Fig. 4C).
Figure 4D represents control for insulin stain-
ing. Finally, examination of the injection site,
as well as liver and spleen for extra-pancreatic
rat mRNA by RT-PCR consistently identified
insulin mRNA in the muscle injection site only
in the non-diabetic animals. Animals that had
received vLP-1 but became diabetic did not
express insulin mRNA and were used as an
internal control. Figure 5A shows a representa-
tive experimental animal expressing rat insulin
mRNA from the injection site (lane 6) but not
in other tissues. Tissues from a diabetic experi-
mental animal did not show any insulin
mRNA expression including at the injection
site (Lanes 1-3). Beta-actin RT-PCR was
performed on the same samples to ensure the
presence of intact mRNA (Fig. 5B). Control
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FIGURE 4 (A) H&E staining of the representative experimental and control animal pancreata showing no difference in the
presence of insulinitis. (B) Representative tissues of an experimental animal showing no immune infiltration at any organ site
including the injected muscle. (C) Pancreas obtained from normoglycaemic NOD mice at 16 weeks as control, showing normal
staining of pancreas islets. (D) Pancreas obtained from NOD mouse at 16 weeks showing absence of insulin stained islets
(stained with anti-insulin antibody).
non-injected animals did not express rat
insulin mRNA (data not shown). The level of
circulating insulin was examined using a rat
insulin RIA. Despite the presence of overt
insulinitis as determined by histology, animals
with normal blood sugars at 16 weeks had
higher levels of insulin than diabetic experi-
mental animals and diabetic controls (Fig. 6).
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spleen (control)
uninjected muscle
liver (control)
pancreas (rat)
spleen(injected)
muscle (injected)
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(B) DISCUSSION
FIGURE 5 (A) Insulin RT-PCR of an experimental animal
liver, spleen and muscle (lanes 5-7) showing expression of
insulin only at the injection site. An experimental animal that
did not respond to treatment was used as a negative control
(lanes 1-3). Rat pancreas was used as a positive control (lane
4). (B) Beta-actin RT-PCR of the same samples showing intact
mRNA in all samples. Representative experiment of 3 with
similar results.
Animals in which the serum glc was tested
were the same animals that underwent
RT-PCR.
Among the several animal models available for
study of human type 1DM, the autoimmune
model is the most extensively investigated.
Utilizing the NOD mouse model of type 1DM, it
was found that insulinitis resulted in destruction
of pancreatic islets. Various immunomodulatory
mechanisms have been able to reverse DM in
NOD mice. [71 We have taken a novel approach to
prevent DM in this model by supplying extra-
pancreatic insulin via rAAV gene therapy. The
basis of this approach is multifactorial. First,
simple production of low levels of insulin in the
prediabetic state has been shown to delay the
onset of clinical diabetes, tll Second, by produc-
ing a steady state of insulin, the opposing
endocrine pathways could provide the neces-
sary balance by the counter-regulatory system,
i.e., glucagon producing alpha-cells of the
pancreas which are not affected by DM. Finally,
while low levels of insulin may not provide
complete respite from hyperglycemia, basal
Insulin (ng/ml)
1.0./
0.8-
0.4--
0.2--
0.0-
Control Treated-NR Treated-R
FIGURE 6 Circulating serum insulin in control diabetic, experimental animals that did not respond to treatment (Treated-
NR), and experimental that responded to treatment (Treated-R) (N 3). Numbers inside individual bars indicate serum glu-
cose at time of sacrifice. Normal nondiabetic NOD serum insulin was 1.3ng/ml + 0.1.
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levels would likely provide better diabetic con-
trol, and thereby, prevent the secondary compli-
cations of DM.
NOD mice develop a lymphocytic infiltrate
in the pancreatic islets causing insulinitis at
approximately 5-6 weeks of age and progress to
overt diabetes by 12-14 weeks by an auto-
immune process. It is postulated that the NOD
model most closely resembles human type I DM.
Previous work has shown that numerous agents
have prevented DM in the NOD mouse mod-
el. In particular, mechanisms that modulate
cytokine profile appeared to prevent onset of
DM; IL-4, IL-10 and TGF-/ were effective. Isl
Transfer of either T-suppressor cells of TGF-/
producing clones prevented DM [9] and treat-
ment with anti-CD40 monoclonal antibody also
completely prevented insulinitis.I11 Mixed allo-
geneic chimerism has also been found to be
effective in preventing insulinitis.I11 Further-
more, experiments in pregnant NOD mice also
inhibited progression of DM, as it is well known
that pregnancy is an immune-privileged state.I121
Other exogenously administered agents such as
Linomide [13] and certain specific peptides [14]
were also effective in preventing DM in NOD
mice. Finally, introduction of gene mutations
and MHC Class II genes also resulted in the pre-
vention ofDM in the NOD mice. [15,16]
Another method of preventing DM is by sup-
plying an alternative source of insulin such as by
pancreatic islet transplants. Transplantation of
islets utilizing semi-permeable membranes was
partially successful in the prevention of DM. [17]
Pretreatment of islets with various compounds
also prolonged islet survival but did not impact
the insulinitis.I181 The limitations of allogeneic
islet cell transplantation in NOD are no different
than that seen in humans, including the need of
immunosuppressive agents.
In these experiments, we have provided an
endogenous source of insulin by injecting the
insulin gene into the skeletal muscle. Insulin
released from the muscle tissues was adequate
to prevent DM. We found mRNA by RT-PCR at
the site of injection without obvious pathological
damage to the muscle or other organs. The
degree of insulinitis in NOD mice receiving
vLP-1 was similar to controls despite the fact
that blood glc and weight of vLP-l-injected ani-
mals was near-normal. These results suggested
that vLP-1 produced insulin did not prevent the
development of insulinitis. Our results are in
contrast to that of Jansen et al. [9] who showed
that prophylactic insulin treatment of NOD
mice decreased insulinitis onset; H&E staining
of pancreata showed decreased islet size and
lower attraction of infiltrating macrophages.
Experiments reported here were not intended to
prevent insulinitis, but rather to provide an
alternative route of endogenous insulin delivery.
Likewise, since it has been reported that viruses
can alter the autoimmune response, it could be
argued that our animals were protected from
insulinitis secondary to the viral proteins chang-
ing surface MHC expression. We discount this
possibility as pancreata in both groups of ani-
mals developed an equal degree of insulinitis
(reviewed blindly by a pathologist). Further-
more, there was complete absence of insulin
staining in pancreas obtained from NOD mouse
at week 16 (Fig. 4C) confirming the fact that
there was no spontaneous reversal of insulinitis.
The presence of insulin message confined to
the site of the injection in the muscle is note-
worthy. Reports have shown that other genes
when delivered to muscle via rAAV "leak" into
the circulation and are detected in hepatocytes
and other tissues. [21 In our experiments, other
tissues were negative for the insulin gene. Fur-
thermore, there was no histopathological
damage to the muscle at the site of injection or
to other mouse organs. These findings suggest-
ed that at least in the short-term there was
no deleterious immunological response to the
injected virus. Further doses of the virus could
be delivered at regular intervals in the clinical
setting.
We investigated the level of circulating insulin
in the animals that were examined by histology
and RT-PCR. Even though there was more circu-
lating insulin in the experimental, non-diabetic
animals, it is difficult to determine the true out-
put of our construct. We know of no RIA that is
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rat insulin specific without cross-reactivity in the
mouse. Furthermore, we did not look for the
levels of pre-proinsulin and proinsulin. It is pos-
sible that these moieties may have also con-
tributed to euglycemia. However, the presence
of mRNA as detected by RT-PCR, and the
increased amount of circulating insulin lead us
to believe that our construct was responsible
for the majority of insulin in the 16 week non-
diabetic animals. With the currently available
assays, it is not possible to say with certainty
that preproinsulin encoded by the gene con-
struct is enzymatically processed to insulin. It is
known that a sizeable portion of the proinsulin
that enters the immature granules of golgi net-
work may be unprocessed and this portion may
escape from the circulation. Unprocessed proin-
sulin has 70% cross reactivity with insulin
measuring reagents. This would also explain
the high plasma glucose levels accompanied by
highest plasma insulin value in one of the three
animals studied. Secondly, the NOD mice may
have insulin receptor antibody which could per-
haps explain high glucose and high insulin lev-
els in this animal.
The question has been raised whether an
insulin-specific promoter instead of RSV is nec-
essary for gene therapy of diabetes. This issue is
being explored in our laboratory. We have con-
structed a vector containing the preproinsulin II
driven by RIP-1 to test the hypothesis that a spe-
cific promoter will result in tighter glc control. In
vitro experiments comparing this vector against
vLP-1 are in progress. Recently, Lee et al. [211 have
shown that using rAAV that expresses a single
chain insulin analogue under control of hepato-
cyte-specifi L-type pyruvate kinase promoter
was able to reverse diabetes in both STZ and
NOD mice up to 5 months. In these experiments,
viral particles were injected into the portal vein,
a relatively invasive procedure. Our method of
delivery of intra-muscular injection is simpler
and more clinically relevant. However, we agree
that more efficient vectors using a variety of
delivery techniques will have to be investigated
before a clinical trial of gene therapy for diabetes
is contemplated.
We postulate, based on indirect evidence, that
there was some form of autoregulation of the
blood glc in the experimental animals. None of
our animals showed overt hypoglycemia and
had normal weight gain. It is possible that the
baseline production of insulin may have been
offset by increased secretion of glucagon by the
alpha cells which are unaffected by insulinitis,
or that the presence of glucose sensing genes
in the muscle regulated the release of insulin
from our construct. Further studies are planned
to perform oral glucose tolerance tests and
counter-regulatory hormones in animals treated
with insulin gene versus animals not receiving
the gene.
We conclude that the rAAV vector is an effi-
cient way to mediate gene transfer. This work
represents the first successful attempt at gene
therapy of DM. We were able to successfully
transfer the rat preproinsulin gene IM and
obtain expression in vivo and prevent overt DM.
Experiments are currently in progress to treat
NOD mice which have overt DM.
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